目的探讨拉米呋啶(LMV)对HBVDNA阳性肺结核患者肝功能干预作用。
Aim To explore the effect lamivudine (LMV) on the liver function of patients with HBV DNA positive pulmonary tuberculosis.
结论：拉米呋啶能抑制HBV的复制，降低血alt水平，促进血清的转换，有效且安全。
Conclusion: Oral lamivudine effectively suppressed HBV replication, decreased ALT level improved serum conversion and it was safe.
上月葛兰素分发了推动4年拉米呋啶方案的小册子，在太平洋岛屿的背景上加上了对自己有利的统计数字。
Glaxo flier last month promoted a four-year regimen of lamivudine, with favorable statistics superimposed on a Pacific island scene.
研究小组注意到，自1997年开始，拉米呋啶就被应用于乙肝病毒PCR阳性和移植后病毒载量升高的患者。
"Since 1997, lamivudine was used when hepatitis B PCR was positive or when the level of post-transplant viral load rose," the team notes.
方法采用实时荧光定量pcr、ELISA及速率法分别检测60例乙肝患者经拉米呋啶治疗后其血清YMDD、HBVDNA、乙肝标志物及alt的变化情况。
Methods the serum YMDD mutation, HBV DNA, ALT and HbeAg levels of 60 patients on lamivudine therapy were detected by FQ-PCR, ELISA, and rate method, respectively.
方法采用实时荧光定量pcr、ELISA及速率法分别检测60例乙肝患者经拉米呋啶治疗后其血清YMDD、HBVDNA、乙肝标志物及alt的变化情况。
Methods the serum YMDD mutation, HBV DNA, ALT and HbeAg levels of 60 patients on lamivudine therapy were detected by FQ-PCR, ELISA, and rate method, respectively.
应用推荐